PDF(Pubmed)
Abstract：
Limited information is available on the effectiveness of COVID-19 vaccination in patients with psoriasis and psoriatic arthritis (psoriatic disease (PsD)). The objective of our research was to assess the effectiveness of mRNA COVID-19 vaccination in preventing SARS-CoV-2 positivity and severe infection in a cohort of patients with PsD and the association of immunosuppressants on SARS-CoV-2 infection-related outcomes from December 2020 to December 2021. Vaccine effectiveness was assessed in a matched nested case control study using conditional logistic regression adjusted for demographics, comorbidities and immunosuppressant use. Study outcomes included SARS-CoV-2 positivity and severe COVID-19 (moderate-to-severe COVID-19-related hospitalizations or death). At least one dose of mRNA COVID-19 vaccine was associated with reduced risk of SARS-CoV-2 positivity and severe COVID-19 (OR = 0.41 (95% CI, 0.38-0.43) and OR = 0.15 (95% CI, 0.11-0.20), respectively). A more significant effect was found among patients who received three vaccines doses compared with those who did not receive any (OR (for positive SARS-CoV-2) = 0.13 (95% CI, 0.12-0.15) and OR (for severe disease) = 0.02 (0.01-0.05)). Etanercept and methotrexate were associated with higher risk of SARS-CoV-2 positivity (1.58 (1.19-2.10), p = 0.001 and 1.25 (1.03-1.51), p = 0.03, respectively). In conclusion, our results show that mRNA COVID-19 vaccines are effective in reducing both infection and severe COVID-19-related outcomes.
摘要：
关于COVID-19疫苗在银屑病和银屑病关节炎（银屑病疾病（PsD））患者中的有效性的信息有限。我们研究的目的是评估2020年12月至2021年12月，在PsD患者队列中，COVID-19mRNA疫苗在预防SARS-CoV-2阳性和严重感染中的有效性，以及免疫抑制剂与SARS-CoV-2感染相关结局的关系。在匹配的巢式病例对照研究中，使用根据人口统计学调整的条件逻辑回归评估疫苗有效性。合并症和免疫抑制剂的使用。研究结果包括SARS-CoV-2阳性和严重COVID-19（中度至重度COVID-19相关的住院或死亡）。至少一剂COVID-19mRNA疫苗与SARS-CoV-2阳性和严重COVID-19的风险降低相关（OR=0.41（95％CI，0.38-0.43）和OR=0.15（95％CI，0.11-0.20），分别)。与未接受任何疫苗的患者相比，接受三种疫苗剂量的患者的效果更为显着（OR（对于SARS-CoV-2阳性）=0.13（95％CI，0.12-0.15）和OR（对于严重疾病）=0.02（0.01-0.05））。依那西普和甲氨蝶呤与SARS-CoV-2阳性的高风险相关（1.58（1.19-2.10），p=0.001和1.25（1.03-1.51），分别为p=0.03)。总之,我们的结果表明,mRNACOVID-19疫苗可有效降低感染和严重的COVID-19相关结局.
